Show source-provided references
3. Coronary Stents: Historical Development, Current Status and Future Directions
10.1093/bmb/ldt009 ↗4. Ueda, P., Gulayin, P., and Danaei, G. (2018). Long-Term Moderately Elevated LDL-Cholesterol and Blood Pressure and Risk of Coronary Heart Disease. PLoS ONE, 13.
10.1371/journal.pone.0200017 ↗7. Stable Coronary Artery Disease: Treatment
8. Coronary Artery Bypass Grafting versus Percutaneous Intervention in Coronary Revascularization: A Historical Perspective and Review
11. Kaplan, J.A., Cronin, B., and Maus, T.M. (2019). Essentials of Cardiac Anesthesia for Noncardiac Surgery, Elsevier.
12. Long-Term Efficacy of Biodegradable Metal-Polymer Composite Stents after the First and the Second Implantations into Porcine Coronary Arteries
10.1021/acsami.0c00971 ↗20. Response to Letter Regarding Article, “Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization”
10.1161/CIRCULATIONAHA.107.727040 ↗21. Drug-Eluting Stent Thrombosis
23. The Development of Bioresorbable Composite Polymeric Implants with High Mechanical Strength
10.1038/nmat5016 ↗24. A Novel Approach to Temporary Stenting: Degradable Cardiovascular Stents Produced from Corrodible Metal-Results 6–18 Months after Implantation into New Zealand White Rabbits
10.1136/heart.86.5.563 ↗25. Strategy of Metal–Polymer Composite Stent to Accelerate Biodegradation of Iron-Based Biomaterials
10.1021/acsami.7b15206 ↗27. Metals and Metal Derivatives in Medicine
29. Biodegradable Stents and Non-Biodegradable Stents
30. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
10.1056/NEJMoa012843 ↗36. Genous Endothelial Progenitor Cell Capturing Stent vs. the Taxus Liberte Stent in Patients with De Novo Coronary Lesions with a High-Risk of Coronary Restenosis: A Randomized, Single-Centre, Pilot Study
10.1093/eurheartj/ehp476 ↗37. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice the COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularizat
10.1016/j.jcin.2015.03.028 ↗38. Long-Term Follow-Up of the Randomised Controlled Trial to Evaluate the Safety and Efficacy of the Zotarolimus-Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions: Five Year Outcomes in the ENDEAVOR II Study
10.4244/EIJV6I5A95 ↗39. The “Final” 5-Year Follow-Up from the ENDEAVOR IV Trial Comparing a Zotarolimus-Eluting Stent with a Paclitaxel-Eluting Stent
10.1016/j.jcin.2012.12.123 ↗40. A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions: 12-Month Outcomes from the ENDEAVOR IV Trial
10.1016/j.jacc.2009.08.067 ↗41. Late-Term Clinical Outcomes with Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (a Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System versus the Cypher Sirolimus-Eluting Coro
10.1016/j.jcin.2010.12.014 ↗42. A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients: The TWENTE Trial
10.1016/j.jacc.2012.01.008 ↗43. 5-Year Results of a Randomized Comparison of XIENCE V Everolimus-Eluting and TAXUS Paclitaxel-Eluting Stents: Final Results From the SPIRIT III Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patient
10.1016/j.jcin.2013.07.009 ↗44. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents: 2-Year Follow-Up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial
10.1016/j.jacc.2011.02.022 ↗45. The SPIRIT V Diabetic Study: A Randomized Clinical Evaluation of the XIENCE V Everolimus-Eluting Stent vs the TAXUS Liberté Paclitaxel-Eluting Stent in Diabetic Patients with De Novo Coronary Artery Lesions
10.1016/j.ahj.2012.02.006 ↗46. Everolimus-Eluting Xience V/Promus Versus Zotarolimus-Eluting Resolute Stents in Patients with Diabetes Mellitus
10.1016/j.jcin.2013.12.201 ↗47. Comparison of Everolimus- and Paclitaxel-Eluting Stents in Patients with Acute and Stable Coronary Syndromes: Pooled Results from the SPIRIT (A Clinical Evaluation of the XIENCE v Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimu
10.1016/j.jcin.2011.06.018 ↗48. Fabrication of Balloon-Expandable Self-Lock Drug-Eluting Polycaprolactone Stents Using Micro-Injection Molding and Spray Coating Techniques
10.1007/s10439-010-0075-6 ↗51. The ABSORB Bioresorbable Vascular Scaffold: An Evolution or Revolution in Interventional Cardiology?
52. Bioresorbable Scaffolds for Percutaneous Coronary Interventions
54. A Next-Generation Bioresorbable Coronary Scaffold System: From Bench to First Clinical Evaluation: 6- and 12-Month Clinical and Multimodality Imaging Results
10.1016/j.jcin.2013.07.007 ↗56. DESyne Novolimus-Eluting Coronary Stent Is Superior to Endeavor Zotarolimus-Eluting Coronary Stent at Five-Year Follow-Up: Final Results of the Multicentre EXCELLA II Randomised Controlled Trial
10.4244/EIJY15M10_04 ↗57. Impact of Strut Thickness on Acute Mechanical Performance: A Comparison Study Using Optical Coherence Tomography between DESolve 150 and DESolve 100
10.1016/j.ijcard.2017.05.087 ↗59. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study
10.1016/j.jcin.2017.07.033 ↗60. Bioresorbable Scaffolds in the Treatment of Coronary Artery Disease
63. Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold
10.1161/CIRCINTERVENTIONS.116.004253 ↗65. Wu, Y., Shen, L., Wang, Q., Ge, L., Xie, J., Hu, X., Sun, A., Qian, J., and Ge, J. (2012). Comparison of Acute Recoil between Bioabsorbable Poly-L-Lactic Acid XINSORB Stent and Metallic Stent in Porcine Model. J. Biomed. Biotechnol., 2012.
10.1155/2012/413956 ↗66. A Head to Head Comparison of XINSORB Bioresorbable Sirolimus-Eluting Scaffold versus Metallic Sirolimus-Eluting Stent: 180 Days Follow-Up in a Porcine Model
10.1007/s10554-017-1148-5 ↗70. Tenekecioglu, E., Farooq, V., Bourantas, C.V., Silva, R.C., Onuma, Y., Yilmaz, M., and Serruys, P.W. (2016). Bioresorbable Scaffolds: A New Paradigm in Percutaneous Coronary Intervention. BMC Cardiovasc. Disord., 16.
10.1186/s12872-016-0207-5 ↗71. TCT-546 6-Month Angiographic Results of the Novel MIRAGE Microfiber Sirolimus-Eluting Bioresorbable Vascular Scaffold—A Quantitative Coronary Angiography Analysis from the Prospective, Randomized MIRAGE Clinical Trial
10.1016/j.jacc.2015.08.563 ↗74. Comparison of a Drug-Free Early Programmed Dismantling PDLLA Bioresorbable Scaffold and a Metallic Stent in a Porcine Coronary Artery Model at 3-Year Follow-Up
10.1161/JAHA.117.005693 ↗75. Head-to-Head Comparison of a Drug-Free Early Programmed Dismantling Polylactic Acid Bioresorbable Scaffold and a Metallic Stent in the Porcine Coronary Artery: Six-Month Angiography and Optical Coherence Tomographic Follow-Up Study
10.1161/CIRCINTERVENTIONS.113.000738 ↗76. Current and Future Perspectives on Drug-Eluting Bioresorbable Coronary Scaffolds
10.2217/fca.14.14 ↗79. Safety and Performance of the Second-Generation Drug-Eluting Absorbable Metal Scaffold in Patients with de-Novo Coronary Artery Lesions (BIOSOLVE-II): 6 Month Results of a Prospective, Multicentre, Non-Randomised, First-in-Man Trial
10.1016/S0140-6736(15)00447-X ↗80. Safety and Performance of the DRug-Eluting Absorbable Metal Scaffold (DREAMS) in Patients with De Novo Coronary Lesions: 3-Year Results of the Prospective, Multicentre, First-in-Man BIOSOLVE-I Trial
10.4244/EIJ-D-15-00371 ↗81. A Word of Caution: Early Failure of Magmaris® Bioresorbable Stent after Pulmonary Artery Stenting
10.1002/ccd.30487 ↗82. Gallic Acid and Gallic Acid-Loaded Coating Involved in Selective Regulation of Platelet, Endothelial and Smooth Muscle Cell Fate
10.1039/C3RA44217A ↗84. Effect of Stent Size on Complications and Recurrent Dysphagia in Patients with Esophageal or Gastric Cardia Cancer
10.1016/j.gie.2006.12.018 ↗85. Determination of Patient-Specific Airway Stent Fit Using Novel 3D Reconstruction Measurement Techniques: A 4-Year Follow-Up of a Patient
10.1177/17534666221137999 ↗86. Alexy, R.D., and Levi, D.S. (2013). Materials and Manufacturing Technologies Available for Production of a Pediatric Bioabsorbable Stent. Biomed. Res. Int., 2013.
10.1155/2013/137985 ↗88. Image-Guided Tissue Engineering of Anatomically Shaped Implants via MRI and Micro-CT Using Injection Molding
10.1089/ten.tea.2007.0186 ↗90. Synthesis and 3D Printing of Biodegradable Polyurethane Elastomer by a Water-Based Process for Cartilage Tissue Engineering Applications
10.1002/adhm.201400018 ↗93. Optimization of Fused Deposition Modeling Process Parameters: A Review of Current Research and Future Prospects
10.1007/s40436-014-0097-7 ↗94. Biodegradable and Bioactive Porous Scaffold Structures Prepared Using Fused Deposition Modeling
10.1002/jbm.b.32863 ↗95. Konta, A., García, M., and Serrano, D. (2017). Personalised 3D Printed Medicines: Which Techniques and Polymers Are More Successful?. Bioengineering, 4.
10.3390/bioengineering4040079 ↗98. 3D-Printed Multidrug-Eluting Stent from Graphene-Nanoplatelet-Doped Biodegradable Polymer Composite
10.1002/adhm.201700008 ↗100. 3D Printed Self-Expandable Vascular Stents from Biodegradable Shape Memory Polymer
10.1002/adv.22091 ↗